Here, we show INPP4B overexpression does not affect the sensitivity of ER+ breast cancer cells to current standard-of-care therapies, but results in enhanced sensitivity to the FDA-approved Wnt inhibitor pyrvinium or 4-OHT-pyrvinium combination treatment in monolayer and 3D cultures. Here, INPP4B is linked to breast carcinoma.